Advertisement

Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration

Twelve-Month Results of the DENALI Study

      Purpose

      To demonstrate noninferiority of ranibizumab in combination with verteporfin photodynamic therapy (PDT) versus ranibizumab monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

      Design

      Prospective, multicenter, double-masked, randomized, phase IIIb clinical trial.

      Participants

      Three hundred twenty-one patients randomized to receive either ranibizumab 0.5 mg monotherapy (n = 112), standard fluence (SF) verteporfin PDT combination therapy (n = 104), or reduced fluence (RF) verteporfin PDT combination therapy (n = 105).

      Methods

      Ranibizumab was administered monthly in the monotherapy group. In both combination therapy groups, ranibizumab was initiated with 3 consecutive monthly injections, followed by retreatment as needed (pro re nata) with monthly monitoring. All patients were evaluated monthly for 12 months.

      Main Outcome Measures

      Mean change in best-corrected visual acuity (BCVA) from baseline at month 12 and proportion of patients randomized to either combination therapy with a ranibizumab treatment-free interval of 3 months or longer.

      Results

      Two hundred eighty-six patients (89.1%) completed the 12-month study. Mean BCVA change at month 12 was +5.3 and +4.4 letters with verteporfin SF (n = 103) or verteporfin RF (n = 105) plus ranibizumab, respectively, compared with +8.1 letters with ranibizumab monotherapy (n = 110; adjusted 97.5% confidence interval [CI], (−7.90 to infinity); P = 0.0666; and 97.5% CI, (−8.51 to infinity); P = 0.1178; for combination regimens vs. monotherapy, respectively). Noninferiority of either combination regimen to monthly ranibizumab monotherapy was not demonstrated (primary end point). A ranibizumab treatment-free interval of 3 months or longer was achieved in 92.6% and 83.5% of the patients randomized to verteporfin SF or verteporfin RF groups, respectively, with a mean of 5.1 and 5.7 ranibizumab injections, respectively, and patients in the ranibizumab monotherapy arm received 10.5 injections. At month 12, mean central retinal thickness decreased by 151.7 μm and 140.9 μm for the verteporfin SF and RF groups, respectively, and by 172.2 μm with ranibizumab monotherapy. Safety and tolerability of all 3 regimens were similar to and consistent with previous studies in neovascular AMD. The number of ocular serious adverse events was low and occurred largely as single cases.

      Conclusions

      Ranibizumab monotherapy or combined with verteporfin PDT improved BCVA at month 12; however, noninferiority (7-letter margin) of combination regimens to ranibizumab monotherapy was not demonstrated. Verteporfin RF did not confer clinical benefits over verteporfin SF. All treatments were well tolerated.

      Financial Disclosure(s)

      Proprietary or commercial disclosure may be found after the references.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kaiser P.K.
        Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration.
        Curr Med Res Opin. 2007; 23: 477-487
        • Aiello L.P.
        • Northrup J.M.
        • Keyt B.A.
        • et al.
        Hypoxic regulation of vascular endothelial growth factor in retinal cells.
        Arch Ophthalmol. 1995; 113: 1538-1544
        • Antonetti D.A.
        • Barber A.J.
        • Hollinger L.A.
        • et al.
        Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopathy and tumors.
        J Biol Chem. 1999; 274: 23463-23467
        • Harhaj N.S.
        • Antonetti D.A.
        Regulation of tight junctions and loss of barrier function in pathophysiology.
        Int J Biochem Cell Biol. 2004; 36: 1206-1237
        • Ishibashi T.
        Cell biology of intraocular vascular diseases [in Japanese].
        Nihon Ganka Gakkai Zasshi. 1999; 103: 923-947
        • Schmidt-Erfurth U.
        • Hasan T.
        Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration.
        Surv Ophthalmol. 2000; 45: 195-214
        • Verteporfin In Photodynamic Therapy Study Group
        Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—Verteporfin in Photodynamic Therapy report 2.
        Am J Ophthalmol. 2001; 131: 541-560
        • Verteporfin in Photodynamic Therapy (VIP) Study Group
        Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—VIP report no. 3.
        Ophthalmology. 2003; 110: 667-673
        • Kaiser P.K.
        • Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group
        Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.
        Graefes Arch Clin Exp Ophthalmol. 2006; 244: 1132-1142
        • Schmidt-Erfurth U.
        • Schlotzer-Schrehard U.
        • Cursiefen C.
        • et al.
        Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor.
        Invest Ophthalmol Vis Sci. 2003; 44: 4473-4480
        • Busch T.
        Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment.
        Retina. 2009; 29: S36-S38
        • Spielberg L.
        • Leys A.
        Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
        Graefes Arch Clin Exp Ophthalmol. 2010; 248: 943-956
        • Visudyne in Minimally Classic Choroidal Neovascularization Study Group
        Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
        Arch Ophthalmol. 2005; 123: 448-457
        • Potter M.J.
        • Claudio C.C.
        • Szabo S.M.
        A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study.
        Br J Ophthalmol. 2010; 94: 174-179
        • Costagliola C.
        • Romano M.R.
        • Rinaldi M.
        • et al.
        Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
        Br J Ophthalmol. 2010; 94: 180-184
        • Ferrara N.
        • Damico L.
        • Shams N.
        • et al.
        Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
        Retina. 2006; 26: 859-870
        • Lowe J.
        • Araujo J.
        • Yang J.
        • et al.
        Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
        Exp Eye Res. 2007; 85: 425-430
        • Brown D.M.
        • Michels M.
        • Kaiser P.K.
        • et al.
        • ANCHOR Study Group
        Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study.
        Ophthalmology. 2009; 116: 57-65
        • Rosenfeld P.J.
        • Brown D.M.
        • Heier J.S.
        • et al.
        • MARINA Study Group
        Ranibizumab for neovascular age-related macular degeneration.
        N Engl J Med. 2006; 355: 1419-1431
        • Holz F.G.
        • Amoaku W.
        • Donate J.
        • et al.
        • SUSTAIN Study Group
        Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN Study.
        Ophthalmology. 2011; 118: 663-671
        • Regillo C.D.
        • Brown D.M.
        • Abraham P.
        • et al.
        • PIER Study Group
        Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
        Am J Ophthalmol. 2008; 145: 239-248
        • Schmidt-Erfurth U.
        • Eldem B.
        • Guymer R.
        • et al.
        • EXCITE Study Group
        Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study.
        Ophthalmology. 2011; 118: 831-839
        • Antoszyk A.N.
        • Tuomi L.
        • Chung C.Y.
        • Singh A.
        • FOCUS Study Group
        Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
        Am J Ophthalmol. 2008; 145: 862-874
        • Schmidt-Erfurth U.
        • Wolf S.
        • PROTECT Study Group
        Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration.
        Br J Ophthalmol. 2008; 92: 1628-1635
        • Larsen M.
        • Schmidt-Erfurth U.
        • Lanzetta P.
        • et al.
        Verteporfin plus Ranibizumab for choroidal Neovascularization in age-related macular degeneration: twelve-month MONT BLANC, study results.
        Ophthalmology. 2012; 119: 992-1001
        • Gupta B.
        • Adewoyin T.
        • Patel S.K.
        • Sivaprasad S.
        Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
        Br J Ophthalmol. 2011; 95: 386-390
        • Boyer D.S.
        • Antoszyk A.N.
        • Awh C.C.
        • et al.
        • MARINA Study Group
        Subgroup analysis of the MARINA Study of ranibizumab in neovascular age-related macular degeneration.
        Ophthalmology. 2007; 114: 246-252
        • Treatment of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Groups
        Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
        Am J Ophthalmol. 2003; 136: 407-418